| 2023-03-28 | +66.9% | legal | SEC EDGAR | PYXS 8-K: 5.02 (SEC Filing) |
| 2025-12-18 | -63.5% | news | Seeking Alpha | Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript |
| 2025-12-18 | -63.5% | news | Seeking Alpha | Pyxis plummets following phase 1 data on candidate for head and neck cancer |
| 2025-12-18 | -63.5% | news | Seeking Alpha | Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma - Slideshow |
| 2025-12-18 | -63.5% | legal | SEC EDGAR | PYXS 8-K: 7.01 and 8.01 (SEC Filing) |
| 2025-12-18 | -63.5% | news | Investing.com | Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com |
| 2025-12-18 | -63.5% | analyst | Investing.com | Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com |
| 2025-12-18 | -63.5% | news | Seeking Alpha | Pyxis plummets following phase 1 data on candidate for head and neck cancer - Seeking Alpha |
| 2025-12-18 | -63.5% | news | GlobeNewswire | Pyxis Oncology Announces Positive Preliminary Phase 1 Data - GlobeNewswire |
| 2024-11-21 | -51.1% | analyst | Seeking Alpha | Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade |
| 2024-11-21 | -51.1% | analyst | Fierce Biotech | Pyxis' shares tumble after early ADC readout in solid tumors fails to spark inspiration: analyst - Fierce Biotech |
| 2024-11-21 | -51.1% | analyst | Seeking Alpha | Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha |
| 2024-11-20 | -50.1% | news | Seeking Alpha | Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset |
| 2024-02-27 | +33.0% | news | Seeking Alpha | Pyxis Oncology stock rises as it looks to raise $50M through a private placement |
| 2025-10-09 | +30.1% | executive | Stock Titan | Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Stock Titan |
| 2022-04-14 | -29.9% | legal | SEC EDGAR | PYXS 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-03-21 | -26.7% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$1.85 beats by $0.10 |
| 2024-03-21 | -26.7% | legal | SEC EDGAR | PYXS 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-01-23 | +22.7% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-03-26 | +22.0% | analyst | TradingView | PYXS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-10-02 | +17.2% | news | Yahoo Finance | Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance |
| 2023-05-24 | -16.9% | legal | SEC EDGAR | PYXS 8-K: 1.01, 5.02, 7.01, 8.01 (SEC Filing) |
| 2024-03-13 | -16.5% | legal | SEC EDGAR | PYXS 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-03-29 | -16.3% | legal | SEC EDGAR | PYXS 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-08-14 | +15.2% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.30 beats by $0.05, revenue of $2.8M |
| 2025-08-14 | +15.2% | legal | SEC EDGAR | PYXS 8-K: 2.02 (SEC Filing) |
| 2022-04-17 | -14.6% | news | TradingView | PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView |
| 2024-03-28 | +14.2% | news | Seeking Alpha | Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait |
| 2026-02-06 | -13.4% | news | Simply Wall St. | 3 Penny Stocks With Market Caps Over $50M To Watch |
| 2025-09-15 | +12.2% | news | Zacks Investment Research | Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross? - Zacks Investment Research |
| 2026-03-31 | +12.1% | legal | Stock Titan | PYXS SEC Filings - Pyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-05-15 | +12.0% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.35 misses by $0.05 |
| 2025-05-15 | +12.0% | legal | SEC EDGAR | PYXS 8-K: 2.02 and 7.01 (SEC Filing) |
| 2022-11-01 | -11.5% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2022-03-31 | -11.5% | news | StockInvest.us | Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? - StockInvest.us |
| 2022-05-13 | -11.0% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2023-03-22 | -10.8% | legal | SEC EDGAR | PYXS 8-K: 2.02 and 5.02 (SEC Filing) |
| 2025-11-03 | +10.6% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.35 in-line |
| 2025-11-03 | +10.6% | legal | SEC EDGAR | PYXS 8-K: 2.02 (SEC Filing) |
| 2025-11-03 | +10.6% | news | GlobeNewswire | Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewswire |
| 2024-03-27 | +10.4% | news | Seeking Alpha | Pyxis Oncology files to sell 10.46M common shares for holders |
| 2024-03-27 | +10.4% | news | Seeking Alpha | Pyxis Oncology gets $8M payment for sale of royalty rights |
| 2024-03-27 | +10.4% | legal | SEC EDGAR | PYXS 8-K: 8.01 and (SEC Filing) |
| 2023-05-11 | +10.4% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2024-12-19 | +10.4% | legal | SEC EDGAR | PYXS 8-K: 8.01 and (SEC Filing) |
| 2021-10-11 | -9.8% | news | Zacks Investment Research | Pyxis Oncology (PYXS) - Zacks Investment Research |
| 2021-10-11 | -9.8% | news | Zacks Investment Research | Should I buy Pyxis Oncology (PYXS) - Zacks Investment Research |
| 2021-10-11 | -9.8% | earnings | Zacks Investment Research | What date does Pyxis Oncology's (PYXS) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2024-11-12 | -9.4% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.35 misses by $0.04 |
| 2024-11-12 | -9.4% | legal | SEC EDGAR | PYXS 8-K: 2.02 (SEC Filing) |
| 2026-03-07 | +8.6% | earnings | ChartMill | PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill |
| 2023-05-25 | -8.5% | M&A | Yahoo Finance | Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up - Yahoo Finance |
| 2023-05-25 | -8.5% | news | CoinCodex | Pyxis Oncology, Inc. (PYXS) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2021-10-09 | -8.4% | earnings | MarketBeat | Pyxis Oncology (PYXS) Stock Price, News & Analysis $PYXS - MarketBeat |
| 2021-10-09 | -8.4% | earnings | MarketBeat | Pyxis Oncology (PYXS) Earnings Date and Reports 2026 $PYXS - MarketBeat |
| 2026-03-23 | -8.2% | news | GlobeNewswire | Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-23 | -8.2% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$1.28 misses by $0.93, revenue of $13.9M |
| 2026-03-23 | -8.2% | legal | SEC EDGAR | PYXS 8-K: 2.02 and 7.01 (SEC Filing) |
| 2026-03-23 | -8.2% | earnings | Stock Titan | Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan |
| 2026-03-23 | -8.2% | analyst | Investing.com | William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com |
| 2026-03-23 | -8.2% | analyst | Investing.com | Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com |
| 2023-09-19 | -8.2% | executive | Seeking Alpha | Pyxis Oncology CEO sells shares worth $18.2k - filing |
| 2023-08-23 | -7.8% | legal | SEC EDGAR | PYXS 8-K: 2.01, 5.02, 7.01 (SEC Filing) |
| 2025-03-18 | -7.8% | legal | SEC EDGAR | PYXS 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2025-12-23 | -7.5% | news | StocksToTrade | Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade |
| 2025-01-13 | -7.4% | news | Intellectia AI | PYXS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2024-12-07 | +7.1% | news | Seeking Alpha | Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead |
| 2024-12-07 | +7.1% | news | Seeking Alpha | Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha |
| 2023-11-07 | -6.7% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2025-10-14 | +5.8% | analyst | Yahoo Finance | Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance |
| 2025-04-25 | -5.3% | news | Stock Titan | PYXS Stock Price, News & Analysis | Pyxis Oncology - Stock Titan |
| 2022-10-07 | -5.3% | legal | SEC EDGAR | PYXS 8-K: 1.01 and 3.02 (SEC Filing) |
| 2025-07-03 | -5.0% | legal | SEC EDGAR | PYXS 8-K: 5.02 (SEC Filing) |
| 2025-03-19 | +4.9% | earnings | Seeking Alpha | Pyxis Oncology reports GAAP EPS of -$1.32 |
| 2022-12-01 | -4.3% | legal | SEC EDGAR | PYXS 8-K: 8.01 and (SEC Filing) |
| 2025-02-26 | -4.3% | legal | Seeking Alpha | Pyxis Oncology rises on FDA fast track tag for lead asset |
| 2025-02-26 | -4.3% | legal | SEC EDGAR | PYXS 8-K: 8.01 (SEC Filing) |
| 2023-06-15 | -4.2% | news | Seeking Alpha | Pyxis: Unique ADC Approach With A Catalyst In Late 2023 |
| 2023-09-07 | -3.9% | M&A | Seeking Alpha | Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed |
| 2024-05-14 | -3.6% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M |
| 2024-05-14 | -3.6% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | +3.5% | news | Yahoo Finance | Pyxis Oncology And 2 Other Promising Penny Stocks To Watch - Yahoo Finance |
| 2026-03-25 | +3.4% | news | Stock Titan | Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan |
| 2026-03-25 | +3.4% | news | Stock Titan | [Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan |
| 2026-03-25 | +3.4% | news | Stock Titan | Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan |
| 2026-03-25 | +3.4% | news | Stock Titan | Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan |
| 2026-03-25 | +3.4% | news | Stock Titan | Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan |
| 2026-03-25 | +3.4% | news | Stock Titan | Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan |
| 2026-03-25 | +3.4% | news | Investing.com | Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com |
| 2022-01-13 | +3.3% | earnings | MarketBeat | Pyxis Oncology (PYXS) Short Interest & Short Float | Updated Apr 2026 $PYXS - MarketBeat |
| 2024-08-14 | -3.2% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2025-06-19 | +3.2% | news | Yahoo Finance | Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14 - Yahoo Finance |
| 2025-06-19 | +3.2% | news | simplywall.st | Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation - simplywall.st |
| 2022-08-09 | -3.0% | legal | SEC EDGAR | PYXS 8-K: 5.02 (SEC Filing) |
| 2026-02-27 | -2.9% | news | AD HOC NEWS | Pyxis Oncology Stock: Can PYXS Survive the Cash Burn And Delisting Risk? - AD HOC NEWS |
| 2025-08-04 | -2.8% | legal | SEC EDGAR | PYXS 8-K: 8.01 (SEC Filing) |
| 2024-06-10 | +2.7% | news | Seeking Alpha | Pyxis Oncology: Promising Research Amid Cash Constraints |
| 2024-06-10 | +2.7% | legal | SEC EDGAR | PYXS 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-06-10 | +2.7% | news | Seeking Alpha | Pyxis Oncology: Promising Research Amid Cash Constraints (NASDAQ:PYXS) - Seeking Alpha |
| 2022-04-26 | +2.6% | news | ChartMill | PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill |
| 2025-01-24 | -2.6% | news | Intellectia AI | PYXS Forecast — Price Prediction for 2026. Should I Buy PYXS? - Intellectia AI |
| 2025-09-07 | +2.4% | news | Finimize | Pyxis’s Cancer Bet Has Paid Off So Far - Finimize |
| 2024-08-08 | +2.3% | news | Seeking Alpha | Pyxis Oncology draws Buy at Stifel on lead asset |
| 2026-04-13 | -2.2% | news | Simply Wall St. | 3 Penny Stocks With Market Caps Under $400M To Consider |
| 2022-08-15 | +2.1% | legal | SEC EDGAR | PYXS 8-K: 2.02, 5.02 (SEC Filing) |
| 2022-08-15 | +2.1% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Pyxis Oncology (PYXS) - Zacks Investment Research |
| 2024-08-15 | -1.9% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.29 |
| 2026-04-06 | -1.9% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03% - Reversal Signals - Cổng thông tin điện tử Tỉnh Sơn La |
| 2021-11-15 | +1.7% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2025-09-12 | +1.7% | analyst | Seeking Alpha | Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) |
| 2025-09-12 | +1.7% | analyst | Seeking Alpha | Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS) - Seeking Alpha |
| 2024-09-13 | -1.5% | news | Seeking Alpha | Moment Of Truth Approaches For Pyxis Oncology |
| 2023-06-30 | +1.2% | legal | SEC EDGAR | PYXS 8-K: 5.02 (SEC Filing) |
| 2026-04-07 | -1.2% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - Stock Community Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2024-05-11 | -1.2% | earnings | MarketBeat | Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS - MarketBeat |
| 2026-04-17 | -1.0% | news | GlobeNewswire | Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 |
| 2026-04-17 | -1.0% | earnings | Stock Titan | Pyxis AACR data: MICVO combo beat either treatment alone - Stock Titan |
| 2024-01-18 | -0.8% | M&A | Seeking Alpha | Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis |
| 2025-08-16 | +0.8% | news | simplywall.st | Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k - simplywall.st |
| 2023-08-11 | +0.7% | earnings | Seeking Alpha | Pyxis Oncology GAAP EPS of -$0.41 |
| 2023-08-11 | +0.7% | legal | SEC EDGAR | PYXS 8-K: 2.02 and (SEC Filing) |
| 2023-08-11 | +0.7% | legal | SEC EDGAR | PYXS 8-K: 8.01 and (SEC Filing) |
| 2026-04-22 | -0.6% | news | Benzinga | 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga |
| 2026-03-24 | +0.5% | news | Investing.com | Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com |
| 2025-02-04 | -0.4% | legal | SEC EDGAR | PYXS 8-K: 8.01 (SEC Filing) |
| 2024-02-28 | -0.4% | legal | SEC EDGAR | PYXS 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2023-11-28 | +0.3% | executive | Seeking Alpha | Pyxis Oncology announces appointment of Kobayashi as CMO |
| 2023-11-28 | +0.3% | legal | SEC EDGAR | PYXS 8-K: 5.02 and (SEC Filing) |
| 2026-02-03 | +0.0% | executive | GlobeNewswire | Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity |
| 2026-02-03 | +0.0% | executive | Stock Titan | Cancer drug developer Pyxis taps CEO behind $1.9B Amgen sale - Stock Titan |
| 2026-04-25 | — | news | Bitget | PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget |
| 2021-10-08 | — | analyst | Benzinga | Pyxis Oncology Analyst Ratings and Price Targets | NASDAQ:PYXS - Benzinga |